For the twelve months ended Sep 30, 2026, Zai Lab Limited reported $441.73M of revenue and -$198.39M of net income.
ZLAB revenueQ3 2026$108.21M
- Quarter YoY
- -6.8%
- QoQ
- +1.8%
- FY YoY
- +15.3%
- 5Y CAGR
- +56.5%
ZLAB revenue was $108.21M in fiscal Q3 2026 (ended Sep 30, 2026), down 6.8% from a year earlier and up 1.8% from the prior quarter. For the full fiscal 2025 it was $460.16M, up 15.3% from fiscal 2024. Compound annual growth was +56.5% over 5 years. It rose in each of the last 7 fiscal years. Fiscal 2025 is the highest of the 8 fiscal years on file.
ZLAB net incomeQ3 2026-$46.14M
ZLAB net income was -$46.14M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$35.96M a year earlier. For the full fiscal 2025 it was -$175.54M, compared with -$257.10M in fiscal 2024.
ZLAB EPSQ3 2026-$0.04
ZLAB diluted EPS was -$0.04 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.03 a year earlier. For the full fiscal 2025 it was -$0.16, compared with -$0.26 in fiscal 2024.
ZLAB free cash flowQ3 2026-$58.81M
ZLAB free cash flow was -$58.81M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$35.05M a year earlier. For the full fiscal 2025 it was -$158.89M, compared with -$220.53M in fiscal 2024.
Source: XBRL data Zai Lab Limited files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 10-for-1, first reported May 10, 2022.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.